Results 71 to 80 of about 2,948 (168)
Кубанский научный медицинский вестник, 2015 The possibility of vardenafil using for pharmacological preconditioning in surgery is studied. Experiment was carried out on Wistar rats. The influence of vardenafil on the survival of pedicled isolated skin flap and the state of the microvasculature in ...
I. M. Kolesnik +2 more
doaj
Pharmaceutics, 2019 Because of poor solubility and considerable metabolism, vardenafil (VRD) bioavailability is 15%. To overcome this obstacle, this study aimed to increase the solubility, hasten the onset of action, and mask the unpleasant taste of VRD utilizing &beta ...
Hytham A. Al-Gethmy +4 more
doaj +1 more source
Classical activation of macrophages and vardenafil [PDF]
Clinical Science, 2017 Inhibitors of phosphodiesterase 5 (PDE5) – sildenafil citrate (Viagra; Pfizer) and vardenafil hydrochloride (Levitra; Bayer/GlaxoSmithKline) – approved for the treatment of erectile dysfunction and pulmonary arterial hypertension also rescue the loss of cystic fibrosis (CF) chloride channel function and the mislocalization of F508del-CFTR in affected ...
openaire +3 more sources
Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
Urological Science, 2016 Erectile dysfunction (ED) is a prevalent form of male sexual dysfunction. Phosphodiesterase type 5 (PDE5) inhibitor is the first-line treatment for ED. Numerous well-designed and -conducted clinical trials and postmarketing studies have established the ...
Bang-Ping Jiann
doaj +1 more source
Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
Clinical Interventions in Aging, 2009 Antonio Martín Morales1, Vincenzo Mirone2, John Dean3, Pierre Costa41Department of Urology, Hospital Carlos Haya, Malaga, Spain; 2Department of Urology, University Federico II, Naples, Italy; 3St.
Antonio Martín Morales +3 more
doaj
Терапевтический архив, 2009 Aim. To study the influence of long-term of vardenafil use on endothelial and erectile functions in patients with arteriogenic erectile dysfunction (ED) Subjects and methods. The study included 74 arteriogenic ED patients (mean age 57.4 ± 4.7 years).
Safar Israilovich Gamidov +7 more
doaj
Erectile dysfunction drugs and oxidative stress in the liver of male rats
Toxicology Reports, 2015 Erectile dysfunction (ED) affected the lives of more than 300 million men worldwide. Erectile dysfunction drugs (EDD), known as phosphodiesterase inhibitors (PDEIs), have been used for treatment of ED.
Salah Sheweita +2 more
doaj +1 more source
Drug Delivery, 2018 Pulmonary arterial hypertension (PAH) can be relieved by pharmacological interventions, especially the targeted drug, which is classified into endothelin receptor antagonist, phosphodiesterase 5 inhibitor, prostaglandin I2, soluble guanylate cyclase ...
Sumei Wang +3 more
doaj +1 more source
Patient Insight and Treatment Expectations in Erectile Dysfunction [PDF]
European Medical Journal, 2016 In the literature, a strong preference towards pharmacological management with oral phosphodiesterase type 5 (PDE5) inhibitors has been demonstrated in men with erectile dysfunction (ED) versus other methods. However, following pharmacological management,
Hartmut Porst
doaj
Sildenafil or Vardenafil Nonresponders’ Erectile Response to Tadalafil
Urology Journal, 2009 Introduction: Erectile dysfunction has usually been treated by a phosphodiesterase 5 inhibitor in men, especially in the past decade. Although sildenafil and vardenafil are widely used, there is a high percentage of people who do not respond to these ...
Berat Cem Ozgur +2 more
doaj